“…The 5-isocyanate analog of NTI, 59-NTII, was the first irreversible nonpeptide DOPr antagonist (Portoghese et al, 1990), which produced long-lasting antagonism of the antinociceptive effects of the DOPr2 agonists DSLET and deltorphin II but not of that of the DOPr1 agonist DPDPE (Jiang et al, 1991;Vanderah et al, 1994). The NTI derivative 9R,13S,2,quinolino [29,19:6,7]morphinan-14-ol(1b) methanesulfonate] showed moderate DOPr binding affinity and DOPr partial agonist activity (Sakami et al, 2008b). A TRK-850 analog, TRK-851 [(5R,9R,13S,14S)-17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-89-fluoro-59,69-dihydro-49H-pyrrolo[3,2,1-ij]quinolino [29,19:6,7]morphinan-3,14-diol(1c) methanesulfonate], also showed DOPr antagonist properties and was metabolically more stable (Sakami et al, 2008a).…”